Poly Medicure Limited ((IN:POLYMED)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Poly Medicure Limited has announced a new clinical study titled An Open-label, Multicentre, Single Arm, Clinical Investigation to Evaluate Performance and Safety of RisoR Crest Everolimus Eluting Coronary Stent System. The study aims to assess the safety and performance of the RisoR Crest Everolimus Eluting Coronary Stent System in treating coronary artery stenosis. This study is significant as it targets both post-market evaluation in India and pre-market evaluation in Europe, involving 2000 participants.
The intervention being tested is the RisoR Crest Everolimus Eluting Coronary Stent System, a device designed to release the drug Everolimus gradually to prevent artery blockage. This stent uses a unique ultrasonic atomization technology for drug delivery.
The study is designed as an interventional, single-group assignment with no masking, focusing on treatment as the primary purpose. It will evaluate the stent’s effectiveness over a 360-day period, with follow-ups at various intervals.
The study is set to begin on August 18, 2025, with an estimated completion date not yet specified. The last update was submitted on July 29, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
This update could positively impact Poly Medicure Limited’s stock performance by showcasing innovation and potential market expansion. Investors may view this as a strategic move to strengthen the company’s position in the medical device industry, particularly against competitors in the coronary stent market.
The study is ongoing, with further details available on the ClinicalTrials portal.